Our Reports
Automotive Reports Electronics & Semiconductor Telecom & IT Technology & IT Consumer Goods Healthcare Food & Beverages Chemical
Our Links
About Us Contact Us Press Release News Our Blogs

Int'l : +1(646) 600-5072 | query@kbvresearch.com


The Worldwide Muscle Relaxant Drugs Market is Projected to reach USD 4.7 Billion by 2029, at a CAGR of 4.3%

Special Offering :

Industry Insights | Market Trends | Highest number of Tables | 24/7 Analyst Support

Muscle Relaxant Drugs Market Growth, Trends and Report Highlights

According to a new report, published by KBV research, The Global Muscle Relaxant Drugs Market size is expected to reach $4.7 billion by 2029, rising at a market growth of 4.3% CAGR during the forecast period.

The Neuromuscular Blocking Agents market is showcasing a CAGR of 4.5% during (2023 - 2029). This is due to the fact that neuromuscular blocking medicines are often used as muscle relaxants. These drugs can make endotracheal intubation go faster, make surgical procedures less difficult, and help with mechanical ventilation. Drugs that inhibit neuromuscular transmission are routinely utilized during surgical procedures. The increasing number of surgical procedures is leading to increased use of neuromuscular blocking drugs.

The Oral market acquired the maximum revenue share in the Global Muscle Relaxant Drugs Market by Route of Administration in 2022 thereby, achieving a market value of $2.6 billion by 2029. This is because the oral way of dosing and administering medications is the most common practice. Furthermore, it is the most commonly used approach because of its many advantages, including the fact that it is non-invasive, improves patient compliance, and makes it simpler to administer medication. In addition, the development of products that may be consumed orally contributes to the expansion of the segment.

The Online Pharmacies market has shown the high growth rate of 5.2% during (2023 - 2029). This is due to the benefits like comfort, convenience, and adaptability, online pharmacies will continue to grow in popularity. These websites also provide patients with a vast array of comparison options and detailed drug information while providing them with numerous discounts and offers, increasing the traffic on their sites and aiding in the segment's expansion during the forecasted period.

The North America market dominated the Global Muscle Relaxant Drugs Market by Region in 2022 thereby, achieving a market value of $1.8 billion by 2029. The Asia Pacific market is anticipated to grow at a CAGR of 5% during (2023 - 2029). Additionally, The Europe market would witness a CAGR of 4.1% during (2023 - 2029).

Full Report: https://www.kbvresearch.com/muscle-relaxant-drugs-market/

The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Amneal Pharmaceuticals, Inc., Ipsen Pharma Biotech SAS, Merz Pharma GmbH & Co. KGaA, Mallinckrodt PLC, Teva Pharmaceuticals Industries Ltd., Eisai Co., Ltd., Endo International PLC, Vertical Pharmaceuticals, LLC, SteriMax Inc., and Metacel Pharmaceuticals, LLC.

Global Muscle Relaxant Drugs Market Segmentation

By Drug Type

  • Skeletal
  • Neuromuscular Blocking Agents
  • Facial Muscle Relaxant Drugs

By Route of Administration

  • Oral
  • Injectable

By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacies

By Geography

  • North America
    • US
    • Canada
    • Mexico
    • Rest of North America
  • Europe
    • Germany
    • UK
    • France
    • Russia
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Singapore
    • Malaysia
    • Rest of Asia Pacific
  • LAMEA
    • Brazil
    • Argentina
    • UAE
    • Saudi Arabia
    • South Africa
    • Nigeria
    • Rest of LAMEA

Companies Profiled

  • Amneal Pharmaceuticals, Inc.
  • Ipsen Pharma Biotech SAS
  • Merz Pharma GmbH & Co. KGaA
  • Mallinckrodt PLC
  • Teva Pharmaceuticals Industries Ltd.
  • Eisai Co., Ltd.
  • Endo International PLC
  • Vertical Pharmaceuticals, LLC
  • SteriMax Inc.
  • Metacel Pharmaceuticals, LLC

Related Reports:



SUBSCRIPTION MODEL